CompletedNCT04417049
Pentoxifylline for Depression in Bipolarity
About this title
Treatment of Bipolar Depression With Pentoxifylline
Read the official source — NCT04417049Medication studyAges 18–65Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Study information
Study start dateStarted: July 12, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 6
- Sponsor
- University Health Network, Toronto
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04417049
- Official title
Show the full official title
Pentoxifylline for Bipolar Depression: A Proof-of-Concept Feasibility Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Health Network, Toronto, a university.
Did this study involve medication?
Yes. The study involved medication, including Pentoxifylline 400 MG.
Who was this study for?
Listed age limits: 18 years to 65 years.
